ABVC Biopharma Inc Cash Flow Conversion Efficiency
ABVC Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, ABVC Biopharma Inc (ABVC) has a cash flow conversion efficiency ratio of -0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-244.41K) by net assets ($12.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ABVC Biopharma Inc (2002–2025)
Cash flow conversion efficiency of ABVC Biopharma Inc from 2002 to 2025. This chart illustrates how ABVC Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABVC Biopharma Inc share price for real-time trading data and today's change.
ABVC Biopharma Inc Cash Flow Conversion Ratio Explained
ABVC Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ABVC Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABVC Biopharma Inc ranked by their cash flow conversion efficiency. Also see ABVC Biopharma Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Epitomee Medical Ltd
TA:EPIT
|
-0.416x |
|
Adval Tech Holding AG
SW:ADVN
|
0.045x |
|
Starteck Finance Limited
NSE:STARTECK
|
0.044x |
|
DDC Enterprise Limited
NYSE:DDC
|
-0.359x |
|
Minesto AB
ST:MINEST
|
-0.057x |
|
Thai Film Industries Public Company Limited
BK:TFI
|
-0.010x |
|
Hansol Pns
KO:010420
|
0.036x |
|
Derwent London PLC
LSE:DLN
|
0.047x |
Annual Cash Flow Conversion Efficiency for ABVC Biopharma Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ABVC Biopharma Inc from 2002 to 2025. Review ABVC Biopharma Inc (ABVC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.30 Million | $-2.99 Million | -0.225x | +91.01% |
| 2024-12-31 | $723.96K | $-1.81 Million | -2.499x | +25.19% |
| 2023-12-31 | $1.25 Million | $-4.19 Million | -3.340x | -107.25% |
| 2022-12-31 | $4.59 Million | $-7.40 Million | -1.612x | -88.16% |
| 2021-12-31 | $8.87 Million | $-7.60 Million | -0.857x | -9.27% |
| 2020-12-31 | $5.82 Million | $-4.56 Million | -0.784x | -103.12% |
| 2019-12-31 | $-124.82K | $-3.13 Million | 25.113x | +22811.16% |
| 2018-12-31 | $-5.75 Million | $-630.20K | 0.110x | +116.02% |
| 2017-12-31 | $2.46 Million | $-1.68 Million | -0.684x | -228.39% |
| 2016-12-31 | $-6.52 Million | $-3.47 Million | 0.533x | +361.25% |
| 2015-12-31 | $29.08K | $3.36K | 0.116x | +202.37% |
| 2014-12-31 | $30.56K | $1.17K | 0.038x | -96.49% |
| 2011-12-31 | $-1.46 Million | $-1.59 Million | 1.088x | +211.17% |
| 2010-12-31 | $-2.99 Million | $-1.05 Million | 0.350x | -54.80% |
| 2009-12-31 | $-2.01 Million | $-1.56 Million | 0.774x | -58.93% |
| 2008-12-31 | $-1.24 Million | $-2.34 Million | 1.884x | +120.31% |
| 2007-12-31 | $290.29K | $-2.69 Million | -9.277x | -1438.21% |
| 2006-12-31 | $35.27K | $24.45K | 0.693x | +328.26% |
| 2005-12-31 | $60.67K | $-18.43K | -0.304x | -256.26% |
| 2004-12-31 | $87.34K | $-7.45K | -0.085x | -2021.11% |
| 2003-12-31 | $80.00K | $355.00 | 0.004x | +100.44% |
| 2002-12-31 | $10.00K | $-10.00K | -1.000x | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more